Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2015 16:05 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the Roth Capital Partners 27th Annual Growth Stock Conference

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as...
February 24, 2015 16:05 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Fourth Quarter and Full Year 2014 Financial Results Conference Call

MacroGenics, Inc. (Nasdaq: MGNX) today announced that on Tuesday, March 3, 2015, the Company will release its financial results for the fourth quarter and full year 2014. The Company's management team...
February 05, 2015 16:00 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the Leerink Global Healthcare Conference

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as...
January 27, 2015 16:10 ET | Source: MacroGenics, Inc.

MacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and...
January 12, 2015 17:45 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the 33rd Annual J.P. Morgan Healthcare Conference

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer,...
December 22, 2014 06:00 ET | Source: MacroGenics, Inc.

MacroGenics Enters Collaboration and License Agreement with Janssen to Develop MGD011 for Multiple B-Cell Malignancies

MacroGenics licenses MGD011 (CD19 x CD3 DART®) to Janssen $50 million upfront license fee paid to MacroGenics, and a $75 million equity investment by Johnson & Johnson Innovation - JJDC,...
December 06, 2014 20:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Presentation of Pre-clinical Data on new DART(r) Candidate MGD011 at 56th Annual Meeting of the American Society of Hematology

Rockville, MD, Dec. 6, 2014 (GLOBE NEWSWIRE) -- December 6, 2014 -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative...
December 03, 2014 07:00 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the Oppenheimer 25th Annual Healthcare Conference

ROCKVILLE, Md., Dec. 3, 2014 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based...
November 12, 2014 16:30 ET | Source: MacroGenics, Inc.

MacroGenics to Present at the Stifel 2014 Healthcare Conference

ROCKVILLE, Md., Nov. 12, 2014 (GLOBE NEWSWIRE) -- ROCKVILLE, Md., November 12, 2014 - MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and...
November 11, 2014 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and Third Quarter 2014 Financial Results

-- Four oncology molecules in clinical development; on track to have six by 2015 year-end -- Margetuximab Phase 3 study in metastatic breast cancer to initiate in 2015 -- MGD007 (gpA33 x CD3...